# US 2025/0367236 A1 · Engineered immune cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367236 A1
- Document ID: US20250367236A1
- Status: Published application
- Kind: A1
- Application number: 18/874,381
- Filed: 2023-06-12
- Published: 2025-12-04
- Earliest claimed: 2022-06-13
- Assignees: Unikum Therapeutics Aps
- Applicants: Unikum Therapeutics Aps
- Inventors: Rasmus Otkjær BAK; Anders LAUSTSEN
- Web page: https://patentgrep.com/patent/US20250367236A1

## CPC

- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 40/19: Dendritic cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/33: Antibodies; T-cell engagers
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 15/86: Viral vectors
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to engineered immune cells expressing synthetic receptors that activate expression of a response element encoding a stimulator of interferon genes (STING) protein, and their use in methods for treating disease, in particular cancer and autoimmune, inflammatory and infectious diseases.

## Claims

### Claim 1

An engineered immune cell that expresses on its surface a synthetic receptor comprising an extracellular antigen recognition domain that recognises an antigen on a target cell, a transmembrane domain, and an intracellular signalling domain that activates expression of a response element in the cell when the extracellular antigen recognition domain binds the target cell, wherein the response element encodes a stimulator of interferon genes (STING) protein.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the cell is:
(c) a lymphoid cell, such as wherein the cell is a natural killer cell, a T cell, a B cell or a plasmacytoid dendritic cell (pDC); or
(d) a myeloid cell, such as wherein the cell is a macrophage.

### Claim 3

The cell of any one of the preceding claims, wherein the synthetic receptor is:
(d) a synthetic intramembrane proteolysis receptor (SNIPR), such as wherein the synthetic receptor is a synthetic RIP family receptor, optionally wherein the receptor is:
(i) synthetic Notch receptor;
(ii) a synthetic Robo receptor; or
(iii) a synthetic RoboNotch receptor;
(e) a Tango receptor; or
(f) a modular extracellular signalling architecture (MESA) system.

### Claim 4

The cell of any one of the preceding claims, wherein the intracellular signalling domain is a transcription factor, optionally wherein the transcription factor comprises a DNA binding domain and a transcriptional activation domain, such as wherein:
(a) the DNA binding domain is selected from the group consisting of Gal4, Pax6, zinc fingers (ZFs), synthetic zinc fingers (synZFs), transcription activator like effectors (TALEs), TetR, HNF1 alpha, and vHNF1 beta; and/or
(b) the transcription activation domain is selected from the group consisting of VP64, VP16, WWTR1, CREB3, NF-κB, p65, Rta, HSF1, and RelA; and/or
(c) the intracellular signalling domain is selected from the group consisting of Gal4-VP64, Gal4-VP16, TetR-VP64, LacI-VP64, HNF1-WWTR1, HNF1-CREB3, Pax6-p65, ZF-p65, synZF-p65, and HNF1-p65.

### Claim 5

The cell of any one of the preceding claims, wherein the extracellular antigen recognition domain is an antibody-derived domain, such as wherein the extracellular antigen recognition domain is an scFv domain.

### Claim 6

The cell of any one of the preceding claims, wherein the STING protein comprises:
(a) a gain-of-function mutation that causes it to be constitutively active in the absence of 2′3′-cGAMP; and/or
(b) a mutation, preferably a substitution, at one or more residues corresponding to R71, S102, V147, N154, V155, G166, C206, G207, G230, H232, R238, F279, R281, R284, R293, or Q315 of SEQ ID NO:1.

### Claim 7

The cell of any one of the preceding claims, wherein:
(a) the cell comprises a heterologous nucleic acid encoding the synthetic receptor; and/or
(b) the cell comprises a heterologous nucleic acid encoding the response element; and/or
(c) the cell comprises a single heterologous nucleic acid encoding the synthetic receptor and the response element.

### Claim 8 (depends on 7)

The cell of claim 7, wherein the heterologous nucleic acid is selected from the group consisting of a viral construct, a plasmid, a cosmid, and an mRNA, optionally wherein:
(a) the viral construct is a lentiviral vector, optionally wherein the lentiviral vector comprises an expression cassette between two LTRs; or
(b) the viral construct is an adenoviral or adeno-associated viral vector, optionally wherein the adenoviral or adeno-associated viral vector comprises an expression cassette between two ITRs; or
(c) wherein the heterologous nucleic acid is introduced using site-specific DNA editing, such as CRISPR/Cas.

### Claim 9 (depends on 8)

The cell of claim 8, wherein the mRNA is delivered via a lipid nanoparticle.

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The cell of any of claims 2-9, wherein the pDC has undergone a step of priming the pDC, optionally wherein the step of priming the pDC comprises incubating the cells with type I IFN and/or type II IFN, such as wherein the pDC is incubated with type I IFN and/or type II IFN for 24 hours.

### Claim 11

The cell of any one of the preceding claims, wherein the STING protein activates an immune response, such as wherein:
(a) the immune response comprises secretion of cytokines, optionally wherein the cytokines modulate the environment of the diseased tissue, or wherein the immune response comprises recruitment or activation of immune cells, such as wherein the cytokines are pro-inflammatory cytokines, optionally wherein the cytokines comprise CXCL10, MCP-1, MCP-2, MIP-1a and/or MIP-1b; and/or
(b) the immune response comprises production of type I IFN.

### Claim 12

A method of treating a disease in a subject, comprising administering the cell of any one of the preceding claims, optionally wherein the disease is:
(e) a cancer;
(f) an autoimmune disease;
(g) an inflammatory disease; or
(h) an infectious disease.

### Claim 13 (depends on 12)

The method of claim 12a, wherein:
(a) the cancer is a solid cancer, such as a cancer selected from the group consisting of: bone cancer, breast cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, prostate cancer, rectal cancer, cancer of the anal region, colon cancer, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, pediatric tumors, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, glioblastoma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer and squamous cell cancer; or
(b) the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL) (including non T cell ALL), acute myeloid leukemia, B cell prolymphocytic leukemia, B-cell acute lymphoid leukemia (“BALL”), blastic plasmacytoid dendritic cell neoplasm, Burkitt s lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloid leukemia, chronic or acute leukemia, diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia, Hodgkin's Disease, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, monoclonal gammapathy of undetermined significance (MGUS), multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma (NHL), plasma cell proliferative disorder (including asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, plasmacytomas (including plasma cell dyscrasia; solitary myeloma; solitary plasmacytoma; extramedullary plasmacytoma; and multiple plasmacytoma), POEMS syndrome (also known as Crow-Fukase syndrome; Takatsuki disease; and PEP syndrome), primary mediastinal large B cell lymphoma (PMBC), small cell- or a large cell-follicular lymphoma, splenic marginal zone lymphoma (SMZL), systemic amyloid light chain amyloidosis, T-cell acute lymphoid leukemia (“TALL”), T-cell lymphoma, transformed follicular lymphoma, and Waldenstrom macroglobulinemia.

### Claim 14

The cell or method of any preceding claim, wherein the antigen is a tumour-associated antigen, such as wherein the antigen is selected from:
(c) the group consisting of CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CS-1, B-cell maturation antigen (BCMA), MAGEA3, MAGEA3/A6, KRAS, CLL1, MUC-1, HER2, EpCam, GD2, GPA7, PSCA, EGFR, EGFRVIII, ROR1, mesothelin, CD33/IL3Ra, c-Met, CD37, PSMA, Glycolipid F77, GD-2, gp100, NY-ESO-1 TCR, FRalpha, CD24, CD44, CD133, CD166, CA-125, HE4, Oval, estrogen receptor, progesterone receptor, uPA, PAI-1, MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 or ULBP6, or a combination thereof; or
(d) the group consisting of 5T4, alphafetoprotein (AFP), B7-1 (CD80), B7-2 (CD86), BCMA, B-human chorionic gonadotropin, CA-125, carcinoembryonic antigen (CEA), carcinoembryonic antigen (CEA), CD123, CD133, CD138, CD19, CD20, CD22, CD23, CD24, CD25, CD30, CD33, CD34, CD4, CD40, CD44, CD56, CD70, CD8, CLL-1, c-Met, CMV-specific antigen, CS-1, CSPG4, CTLA-4, DLL3, disialoganglioside GD2, ductal-epithelial mucine, EBV-specific antigen, EGFR variant III (EGFRvIII), ELF2M, endoglin, ephrin B2, epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), epithelial tumour antigen, ErbB2 (HER2/neu), fibroblast associated protein (fap), FLT3, folate binding protein, GD2, GD3, glioma-associated antigen, glycosphingolipids, gp36, HBV-specific antigen, HCV-specific antigen, HER1, HER2, HER2-HER3 in combination, HERV-K, high molecular weight-melanoma associated antigen (HMW-MAA), HIV-1 envelope glycoprotein gp41, HPV-specific antigen, human telomerase reverse transcriptase, IGFI receptor, IGF-II, IL-11Ralpha, IL-13R-a2, Influenza Virus-specific antigen, CD38, insulin growth factor (IGF1)-1, intestinal carboxyl esterase, kappa chain, LAGA-1a, lambda chain, Lassa Virus-specific antigen, lectin-reactive AFP, lineage-specific or tissue specific antigen such as CD3, MAGE, MAGE-A1, major histocompatibility complex (MHC) molecule, major histocompatibility complex (MHC) molecule presenting a tumour-specific peptide epitope, M-CSF, melanoma-associated antigen, mesothelin, MN-CA IX, MUC-1, mut hsp70-2, mutated p53, mutated p53, mutated ras, neutrophil elastase, NKG2D, Nkp30, NY-ESO-1, p53, PAP, prostase, prostate specific antigen (PSA), prostate-carcinoma tumour antigen-1 (PCTA-1), prostate-specific antigen protein, STEAP1, STEAP2, PSMA, RAGE-1, ROR1, RU1, RU2 (AS), surface adhesion molecule, survivin, telomerase, TAG-72, the extra domain A (EDA) and extra domain B (EDB) of fibronectin and the A1 domain of tenascin-C (TnC Al), thyroglobulin, tumour stromal antigens, vascular endothelial growth factor receptor-2 (VEGFR2), virus-specific surface antigen such as an HIV-specific antigen, or a combination thereof.

### Claim 15 (depends on 12)

The method of claim 12b, wherein the autoimmune disease is selected from the group consisting of type 1 diabetes, thyroid autoimmune disease, Addison's adrenal insufficiency, oophoritis, orchitis, lymphocytic hypophysitis, autoimmune hypoparathyroidism, autoimmune hypoparathyroidism, Goodpasture's disease, autoimmune myocarditis, membranous nephropathy, autoimmune hepatitis, ulcerative colitis, Crohn's disease, multiple sclerosis, myasthenia gravis, neuromyelitis optica, encephalitis and Sjögren's syndrome.

### Claim 16 (depends on 12)

The method of claim 12c, wherein the inflammatory disease is selected from the group consisting of cystic fibrosis, chronic inflammatory intestinal diseases like, for example, ulcerative colitis or Crohn's disease, vasculitis, in particular Kawasaki disease, chronic bronchitis, inflammatory arthritis diseases like, for example, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, and systemic onset juvenile rheumatoid arthritis (SOJRA, Still's disease), graft-versus-host disease, asthma, psoriasis, systemic lupus erythematosus, obesity and inflammatory vascular disease and allograft rejection.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The cell of any of claims 1-11 or the method of any of claims 12b, 12c, 15 or 16, wherein the antigen is expressed on the surface of immune cells that cause autoimmune or inflammatory disease.

### Claim 18 (depends on 12)

The cell or method of claim 12b or claim 12c, wherein the disease is transplant rejection or graft-versus-host disease (GVHD).

### Claim 19 (depends on 12)

The method of claim 12d, wherein the infectious disease is a chronic viral or fungal infection, such as infection of Influenza, Yellow Fever virus, West Nile virus, Hantavirus, Ebola virus, Rotavirus, Norovirus, Rabies virus, Tick-borne encephalitis virus (TBEV), rhinoviruses, Coronavirus, RSV, Measles, Parainfluenza, Zikavirus, Dengue virus, HIV, HBV, HCV, human cytomegalovirus (CMV), Epstein-Barr virus (EBV), Aspergillus spp., such as Aspergillus fumigatus, Candida spp., such as C. albicans, Mucorales, Cryptococcus spp., such as Cryptococcus neoformans or Cryptococcus gattii, or Pneumocystis jirovecii.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 19)

The cell of any of claims 1-11 or the method of claim 12d or claim 19, wherein the antigen is a pathogen antigen, such as wherein the antigen is selected from the group consisting of Yellow Fever virus NS1 protein, West Nile virus NS1 protein, Hantavirus N protein, Ebola virus N protein, Rotavirus VP6, Norovirus VP1, rabies virus N protein, TBEV envelope glycoprotein, rhinovirus VP proteins, Influenza hemagglutinin antigens, Influenza neuraminidase antigens, coronavirus spike protein, RSV F protein, MeV N protein, Parainfluenza hemagglutinin antigens, Parainfluenza neuraminidase antigens, ZIK V E, NS1, NS3, NS4B, and NS5 proteins, Dengue virus C protein, M protein, E protein, NS1 protein, gp120, gp41, Env, HBV surface antigen, HBV surface proteins S and L, HCV E2 glycoprotein, CMV glycoprotein B, fungal beta glucan.

### Claim 21

The cell or method of any one of the preceding claims, wherein the cell has been extracted from blood or bone marrow.

### Claim 22 (depends on 2)

The cell or method of any one of claims 2a-21, wherein the cell has been differentiated in vitro from HSPCs, optionally wherein the HSPCs have been obtained from blood or bone marrow, or wherein the HSPCs have been differentiated in vitro from induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).

### Claim 23

A pharmaceutical composition comprising the engineered immune cell of any preceding claim and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 2)

A method of producing the cell of any one of claims 2a-23, comprising the steps of:
(a)
(i) transfecting or transducing HSPCs with one or more vectors encoding the synthetic receptor and the response element; and
(ii) differentiating the HSPCs into pDCs; or
(b)
(i) differentiating HSPCs into pDCs; and
(ii) transfecting or transducing the pDCs with one or more vectors encoding the synthetic receptor and the response element;
optionally wherein:
(A) the vector is a viral vector, optionally wherein the vector is a lentiviral vector or an adenoviral or adeno-associated viral vector; or
(B) wherein the vector is an mRNA, optionally encapsulated in a lipid nanoparticle.

### Claim 25 (depends on 24)

The method of claim 24, wherein:
(a) the step of differentiating the HSPCs comprises incubating said HSPCs in one or more media, which media may typically comprise one or more cytokines, growth factors, interferons (IFNs) and/or aryl hydrocarbon receptor (AHR) antagonists (such as stemregenin-1), whereby said HSPCs are differentiated into precursor-pDCs and into pDCs; and/or
(b) the method further comprises a step of purifying the pDCs; and/or
(c) the method further comprises a step of formulating the pDCs with a pharmaceutically acceptable excipient.
